Project Grant R01NS147187
Award Date 8/26/26
Completion Date 5/31/31
Dollars Obligated $616K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (Massachusetts General Hospital) $435,550 on August 15, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853, Assistance Listing). The award funds investigator-initiated research examining the role of DNA methyltransferase 3 alpha (DNMT3A) in oligodendrogenesis and white matter repair following ischemic stroke. The project tests the...
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital a $2.541 million cooperative agreement on May 1, 2026, to develop targeted gene repair therapy for multisystem smooth muscle dysfunction syndrome caused by ACTA2 R179H mutation, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds IND-enabling studies for a novel CRISPR/Cas9-directed adenine base editor delivered via AAV-PR...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $322,382 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research investigating cell-specific interleukin-1 receptor 1 (IL-1R1) signaling in focal and diffuse traumatic brain injury models. The research uses genetically engineered mice with precise...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $1.854 million on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds research into compartmentalized reactive oxygen species (ROS) sensing in the brain, specifically investigating how neurons balance mitochondrial energy production with ROS control....
- The National Institute of Neurological Disorders and Stroke awarded Massachusetts General Hospital $439,150 on June 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate exercise preconditioning and compensatory oligodendrogenesis in subcortical ischemic vascular dementia. The research examines white matter damage in vascular contributions to cognitive impairment and dementia, with focus on oligodendrocyte precursor...
- The National Institutes of Health Office of the Director awarded The General Hospital Corporation (Massachusetts General Hospital) $783,750 under the Trans-NIH Research Support program (CFDA 93.310) on September 1, 2026, to conduct therapeutic discovery in neurodegeneration using bioengineered organoids and artificial intelligence-driven genomics approaches. The award funds development of multiplexed differentiation strategies to generate midbrain organoids that integrate all major brain cell...
- The National Institute of Neurological Disorders and Stroke awarded The General Hospital Corporation (Massachusetts General Hospital) $648,672 on June 11, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate circadian regulation of reperfusion efficacy in acute ischemic stroke. The research employs a translational approach combining clinical neuroimaging, biomarkers, mouse models of stroke, CT-PET imaging of tissue...
- The National Institute of General Medical Sciences awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $443,090 under the Biomedical Research and Research Training program (CFDA 93.859) on September 1, 2026. The award funds a five-year research program investigating the mechanisms of perioperative neurocognitive disorder, a neurotoxic condition arising from anesthesia and surgery that is characterized by declines in memory, attention, and executive...
- The National Institute of Neurological Disorders and Stroke awarded President and Fellows of Harvard College $595,961 on September 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to investigate mitochondrial DNA mutations and gene editing approaches in neural dysfunction. The research addresses mechanisms of central nervous system dysfunction triggered by mitochondrial DNA (mtDNA) mutations, particularly mutations in...
- The National Institute of Neurological Disorders and Stroke, a component of the Department of Health and Human Services National Institutes of Health, awarded $614,689 to The General Hospital Corporation (doing business as Massachusetts General Hospital) on August 1, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) to develop patient-based disease-modifying therapeutic strategies for Huntington's disease by targeting FAN1, an...